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Abstract
Background: Remission of multiple sclerosis during periods of high ovarian hormone secretion (such as pregnancy) 
has led to a great deal of interest in the potential for estrogens to treat autoimmune disease. Previous work has 
established that 17β-estradiol can inhibit onset of experimental autoimmune encephalomyelitis (EAE), while ethinyl 
estradiol (EE) can reduce the severity of established disease. In the current study, the influence of estrogen receptor-α 
(ERα) and the G-protein coupled estrogen receptor (GPR30 or GPER) on EE's ability to treat EAE was explored.
Results: EE reduced disease severity in wild-type and ERα knockout (ERKO) mice, but did not alter disease in the 
GPR30KO group. Production of anti-inflammatory IL-10 increased in EE-ERKO mice (which showed reduced disease) 
but not in EE-GPR30KO mice (who did not have improved disease).
Conclusions: Differential production of IL-10 following EE treatment in ERKO and GPR30KO animals may be 
responsible for the distinctly different effects on disease severity. Increased IL-10 in ERKO-EE compared to ERKO-
Controls is likely to be an important factor in reducing established disease. The inability of EE to reduce disease in 
GPR30KO mice indicates an important but still undefined role for GPR30 in regulating immune reactivity.
Background
Multiple sclerosis (MS) is an inflammatory demyelinating
disease, which affects women more often than men [1].
Although women more frequently suffer from MS, remis-
sion of disease symptoms often occurs at times when ovar-
ian hormone levels are high, such as during pregnancy
[2,3]. Using experimental autoimmune encephalomyelitis
(EAE), the animal model of MS, previous work has exam-
ined the mechanisms involved in estrogen's effects on the
immune system. When given prior to immunization, 17β-
estradiol (E2) protects against development of EAE, pri-
marily by decreasing the production of inflammatory
cytokines, increasing anti-inflammatory cytokines (includ-
ing IL-10), and through expansion of regulatory T cells
(such as FOXP3+ and PD1+ cell populations) [4-8]. Inves-
tigations into the estrogen receptors (ER) involved in the
effects of E2 have largely implicated ERα and the G-protein
coupled estrogen receptor (GPR30), while E2 can still pro-
tect mice lacking ERβ [9,10].
Although E2 can protect against the development of
EAE when given subcutaneously prior to immunization
with myelin peptide, it cannot treat established disease
(Offner, unpublished data). Conversely, ethinyl estradiol
(EE) can reduce disease severity when given orally at the
onset of disease symptoms [11]. EE is a synthetic estro-
gen, frequently used in oral contraceptives, which main-
tains its bioavailability after oral dosing, unlike E2 [12]. In
addition to differences in bioavailability, it is possible that
differential activation of estrogen receptors may be
involved in the treatment ability of EE compared to the
ineffectiveness of E2. The protective effects of E2 are lost
in mice lacking ERα (ERKO) but maintained in mice lack-
ing ERβ [9]. Although disease onset is delayed in GPR30-
deficient (GPR30KO) mice pre-treated with E2, much of
the protective effect of E2 on disease severity is lost [10].
In the current study, we used mice lacking ERα and
GPR30 to explore their role in the ability of EE to treat
EAE. Given the importance of changes in the balance of
pro- and anti-inflammatory cytokines and the role of reg-
ulatory T cell populations in the action of E2, we will also * Correspondence: offnerva@ohsu.edu
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examine whether the effects of EE rely on similar mecha-
nisms.
Methods
Animals
Wild-type (WT) female C57BL/6 mice were obtained
f r o m  H a r l a n  L a b o r a t o r i e s  ( H o u s t o n ,  T X ) .  E R K O  a n d
GPR30KO mice were bred using in-house colonies. The
ERKO strain originated with the Korach laboratory and is
on a C57BL/6 background. The generation of ERKO [13]
and GPR30KO mice (also on a C57BL/6 background) [14]
have previously been described. All animals were housed
in the Animal Resource Facility at the Portland VA Medi-
cal Center and experiments were performed in accor-
dance with institutional guidelines. Animals were
ovariectomized at 7-8 weeks of age and immunized 1
week later. Mice were immunized with 200 μg of MOG
35-55 peptide (PolyPeptide laboratories; San Diego, CA)
in 400 μg of complete Freund's adjuvant. Mice were also
injected with pertussis toxin at the time of immunization
(d0; 75 ng) and d2 (200 ng). Animals were observed daily
and scored for disease severity according to the following
scale: 0 = normal, 1 = limp tail, 2 = mild hindlimb weak-
ness, 3 = moderate hindlimb weakness, 4 = severe weak-
ness or partial paralysis, 5 = complete hindlimb paralysis,
6 = moribund. Experiments were completed twice. The
total number of animals in each group was WT: N = 12
per group, ERKO: Control (Ctrl) N = 9, EE N = 10,
GPR30KO: Ctrl N = 13, EE N = 12.
Ethinyl estradiol treatment
At the onset of EAE (first day with a score of 1 or greater,
approximately D11-12 post-immunization), animals were
randomly assigned to receive either ethinyl estradiol (1
mg/day) or control treatment. Treatments were given in a
100 μl volume of olive oil by oral gavage.
Splenocyte analyses
Spleens were collected at D26 post-immunization. Tissues
were homogenized through fine mesh screens and single
cell suspensions were used for cytokine assay and flow
cytometry. Splenocytes (4 × 106/ml) were cultured and
stimulated with MOG 35-55. Supernatants were collected
48 hrs later and frozen at -80°C until the time of cytokine
assay. IL-10 and IL-17 were measured using a bio-plex
luminex kit (Bio-Rad; Hercules, CA). For flow cytometry,
cells were stained using: CD4-FITC and intracellular stain-
ing for FOXP3-APC and PD-1PE was completed after fixa-
tion/permeabilization (EBiosciences; San Diego, CA). Cells
were then run on a FACSCalibur (Becton Dickson).
Statistical analysis
The day of onset, clinical disease scores, and cumulative
disease index within each genotype (Control vs EE) was
compared using t test, as well as WT- Ctrl comparisons to
Control in each genotype. Evaluation of changes in
cytokine levels within each genotype were also completed
using t tests; the accepted level of significance was p < .05.
Results
Disease scores
From D17-D26, disease was significantly inhibited in WT
mice treated with EE (p < .03, Figure 1A). While cumula-
Figure 1 Treatment with ethinyl estradiol (EE; 1 mg/day) reduced 
disease severity in ovariectomized wild-type (WT) mice (A) and 
estrogen receptor-α knockout (ERKO) mice (B), while mice lack-
ing the G-protein coupled estrogen receptor (GPR30KO; C) 
showed no improvement in disease severity. WT: N = 12 per group. 
ERKO: Ctrl N = 9, EE N = 10. GPR30KO: Ctrl N = 13, EE N = 12. * indicates 
p < .04Yates et al. BMC Immunology 2010, 11:20
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tive disease index (CDI) was also reduced (p < .01), dis-
ease onset and peak disease scores did not differ (Table
1). ERKO mice treated with EE also had reduced disease
severity (p < .04; D17-20, 23-26, Figure 1B). Peak disease
scores and CDI were also reduced in ERKO EE animals (p
< .03, Table 1). However, GPR30KO animals showed no
alteration in disease course with EE treatment (Figure 1C
and Table 1). Within Ctrl mice, there was no difference in
peak disease severity or onset between WT-Ctrl and
GPR30KO-Ctrl mice. However, GPR30KO mice did show
lower average disease scores (D16-26) and a reduced CDI
compared to WT (p < .02). There were no differences
between WT-Ctrl and ERKO-Ctrl mice.
Cytokine analysis and flow cytometry
In the presence of antigen, IL-10 production decreased in
EE-GPR30KO mice (p < .02), but increased in IL-10
secretion for EE-ERKO splenocytes (p < .03) compared to
their respective controls (Figure 2). IL-17 levels did not
change significantly between EE or Control mice in either
the ERKO or GPR30KO strains. No significant changes
were seen in FOXP3+ or PD1+ cells in any strain (data
not shown).
Discussion
The present study sought to explore the role of estrogen
receptors in the ability of EE to reduce EAE disease sever-
ity. Expression of ERα and ERβ have been documented on
a variety of immune and CNS cells, including T cells,
macrophages, microglia, oligodendrocytes, and astro-
cytes [15-19], which are involved in EAE disease severity.
Recent investigation are also beginning to delineate
expression of GPR30 in the CNS and immune system, but
results remain mixed [20]. The use of mice lacking ERα or
GPR30 allowed us to more fully examine estrogen recep-
tor involvement in the pathways affected by EE treatment
in EAE.
The effects of EE on WT mice in the current study are
in agreement with previous work demonstrating
decreased disease severity [11]. Expression of GPR30
seems to be crucial in the ability of EE to reduce disease,
as no treatment effect was observed in GPR30KO mice
while ERKO mice maintained their ability to respond to
EE treatment of EAE. The difference in disease scores
between GPR30KO-Ctrl and WT-Ctrl mice is intriguing
but the underlying cause remains unclear. While our pri-
mary interest in the current experiment was the effect of
EE within each genotype, future work will further investi-
gate this divergence between the genotypes.
In an effort to determine specific changes responsible
for the disease inhibition in EE-ERKO but not EE-
GPR30KO mice, we examined cytokine production by
splenocytes in response to antigen, specifically the anti-
inflammatory cytokine IL-10 as well as IL-17 (which
plays a role in inflammation and pathogenesis in EAE;
[21]). Although IL-17 did not change in either strain,
secretion of IL-10 was increased in EE-ERKO mice com-
pared to Controls, but decreased in EE-GPR30KO mice.
This difference in IL-10 production may be an important
contributor to the disease reduction in EE-ERKO mice
compared to the GPR30KO mice which did not improve
with EE treatment. Increased IL-10 secretion is fre-
quently associated with improvement in disease [22,23],
while IL-10 deficient animals have a greater T cell
response to antigen and develop more severe EAE com-
Table 1: Disease was reduced in EE treated WT and ERKO mice compared to their respective controls.
CDI Onset Peak
WT: Ctrl 64.5 (± 2.5) 12.3 (± 0.4) 5.1 (± 0.1)
EE 54.0* (± 1.8) 12.0 (± 0.5) 4.8 (± 0.1)
ERKO: Ctrl 60.5 (± 4.0) 11.7 (± 0.4) 4.8 (± 0.2)
EE 48.5* (± 3.1) 12.2 (± 0.4) 4.2* (± 0.2)
GPR30KO: Ctrl 47.6 (± 5.3) 11.5 (± 0.4) 4.5 (± 0.3)
EE 51.2 (± 4.2) 11.0 (± 0.4) 4.6 (± 0.6)
Cumulative disease index (CDI) was reduced in EE-WT and EE-ERKO mice compared to their respective control groups. Peak disease severity 
was only reduced in ERKO-EE mice. Onset did not differ between any EE and control groups. * indicates p < .03Yates et al. BMC Immunology 2010, 11:20
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pared to WT mice [24]. The subset of cells responsible for
this differential secretion of IL-10 in the current experi-
ment is unclear however, and warrants further investiga-
tion.
Our data in the WT groups also demonstrates the dif-
ferential mechanisms of EE action compared to 17β-
estradiol, which can prevent but not treat EAE after dis-
ease onset. While increases in the FOXP3+ and PD1+
regulatory T cell populations seem to be primary mecha-
nisms of action for 17β-estradiol protection against EAE
[6-8], no changes were found in EE treated animals of any
strain in the current study. In addition, ERα expression is
necessary for 17β-estradiol protection against EAE [9]
but is not crucial in EE treatment since EE-ERKO mice
still improved with EE treatment in the absence of ERα.
Conclusions
The lack of disease improvement in EE treated GPR30KO
mice indicates a crucial role for GPR30 in altering disease
severity, which is likely to be related to the production of
IL-10. Further investigation of the mechanisms behind
the change in IL-10 production will be necessary to
understand the cell populations responsible. In addition,
the responsiveness of ERKO mice to EE treatment indi-
cates that ERα is not a major factor in disease inhibition
due to EE treatment. The presence of both GPR30 and
ERβ in ERKO mice makes it difficult to further narrow
down the receptor specifically implicated in the treat-
ment effect. Use of double knockouts (ERα+GPR30KO or
ERα+GPR30KO) would be necessary to more fully distin-
guish between these pathways.
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